Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

OneSkin

Request full access

A longevity company on a mission to transform the way we think about skin and aging

San Francisco, United StatesFounded 2016Biotech & Life Sciences

About OneSkin

OneSkin is a biotechnology company operating in the longevity and skincare market, founded in 2016 by four female Brazilian scientists: Dr. Carolina Reis Oliveira (CEO), Dr. Alessandra Zonari (CSO), Dr. Mariana Boroni, and Dr. Juliana Carvalho. The founders, who met during their doctoral studies in Brazil, leveraged their collective expertise in immunology, stem cell biology, skin regeneration, and bioinformatics to establish the company. Their journey began not with the intent to create a skincare product, but to test the efficacy of existing anti-aging products on 3D human skin models they were growing in their lab. Discovering that many products were ineffective and some even harmful at a cellular level, they pivoted to develop molecules that could target the root causes of skin aging.

The company's core business revolves around its proprietary peptide, OS-01, developed after screening over 900 peptides. This peptide is the first scientifically shown to reduce skin's biological age by targeting cellular senescence—the accumulation of aged, dysfunctional cells that contribute to wrinkles and loss of firmness. The OS-01 peptide works by preventing this accumulation, supporting cellular repair, and promoting markers associated with collagen and hyaluronic acid production. Lab studies on human skin models demonstrated that the OS-01 peptide could increase epidermal thickness by up to 28% and reduce the skin's biological age by approximately 2.5 years in just five days.

OneSkin's business model is primarily direct-to-consumer (DTC) through its website, with a strong emphasis on a subscription model that accounts for two-thirds of its online sales. The company also distributes its products through Amazon, which constitutes about 10% of sales, and is expanding into wholesale channels to reach professionals like dermatologists and aestheticians. Their product line, which includes topical supplements for the face, body, eyes, lips, and hair, is priced in the premium segment, ranging from $45 to $120. The company's primary markets are the United States, Canada, and the United Kingdom. Its customer base is mainly Gen X and millennial women, but men also represent a significant 20% of its clientele.

Financially, OneSkin has demonstrated significant growth, securing a total of $40.6 million in funding over five rounds. A notable Series A round, led by Selva Ventures with participation from Unilever Ventures, raised $7 million, bringing the company's total funding to $20 million at that time. A subsequent Series B round in May 2025 raised an additional $20.4 million. While the company is profitable, its CEO noted that 2024 revenue estimates of under $10 million were low, stating the company operates at a Series B level in terms of revenue. OneSkin is focused on continued international expansion, new product development, and advancing clinical studies to further validate its technology.

Source: Dealroom company data

At a glance

Status
Operational
Employees
63
Open positions
None listed
Dealroom signal
87.0/100
Industry
Health, Wellness Beauty
Sub-industry
Pharmaceutical, BioTechnology
Sector
Risk Management, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Aug 2025 $20M $80M Prelude Growth Partners ↗
SERIES A✓Equity / VC Nov 2024 $7M $62M Selva Ventures · Unilever Ventures · SOSV · Plus Capital ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

OneSkin website traffic

Latest recorded traffic for OneSkin is 380 monthly website visits, up 40.7% over the last three months. OneSkin's team grew 14.5% over the past year.

Latest monthly visits380 3-month web change+40.7% 1-year team growth+14.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

OneSkin in the San Francisco ecosystem

Live from Dealroom

The OneSkin office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A6 investors entered at this stage

  • Selva Ventures
  • Unilever Ventures
  • Plus Capital
  • Able Partners
  • MetaPlanet
  • Prelude Growth Partners

Other known investors1 additional known investor

  • MBC Biolabs
Team profiled 14 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See OneSkin’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.